Merck Stock Worth Watching on PAH Drug Winrevair's Approval in Europe?

Merck (MRK) announced that the European Commission has granted approval to its novel activin signaling inhibitor, Winrevair (sotatercept), for treating adult patients with pulmonary arterial hypertension (PAH). Winrevair can now be prescribed to treat PAH in adult patients with World Health Organization (WHO) Functional Class (FC) II to III in the EU in combination with other PAH therapies. Winrevair becomes the first novel activin signaling inhibitor therapy approved in Europe to treat PAH.The approval was ...